Equities

Spruce Biosciences Inc

SPRB:NAQ

Spruce Biosciences Inc

Actions
  • Price (USD)0.5007
  • Today's Change-0.011 / -2.05%
  • Shares traded57.29k
  • 1 Year change-51.86%
  • Beta2.3317
Data delayed at least 15 minutes, as of Nov 14 2024 16:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments967989
Total Receivables, Net------
Total Inventory------
Prepaid expenses3.883.322.53
Other current assets, total1.971.210.40
Total current assets1028492
Property, plant & equipment, net1.181.401.65
Goodwill, net------
Intangibles, net------
Long term investments--032
Note receivable - long term------
Other long term assets0.580.640.26
Total assets10486126
LIABILITIES
Accounts payable3.331.432.82
Accrued expenses159.406.05
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.621.620
Other current liabilities, total4.91----
Total current liabilities24128.87
Total long term debt1.723.294.88
Total debt3.344.924.88
Deferred income tax------
Minority interest------
Other liabilities, total1.261.421.37
Total liabilities271715
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital274218215
Retained earnings (accumulated deficit)(197)(149)(103)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0(0.56)(0.18)
Total equity7768111
Total liabilities & shareholders' equity10486126
Total common shares outstanding412423
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.